| September 2010 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
Monthly Archives
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
April 2008
Complete Archives
Most recent entries
SpectraScience Provides Corporate Update and Outlook
SpectraScience appoints Sheldon L. Miller Esq. to its Board of Directors
SpectraScience Receives Notification of Pending Issuance of Two Patents
SpectraScience Retains Quorum Consulting
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
SpectraScience Has Second Unannounced Inspection by FDA
SpectraScience’s Jim Hitchin Featured in MDDI Magazine Article
Health Radio - Interview with CEO, Jim Hichin
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
SpectraScience CEO Jim Hitchin Speaks to Blogtalkradio About Better Cancer Screening Diagnostics
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
SpectraScience Forms Advisory Board - Governor Tommy Thompson to be Chairman
SpectraScience Releases Shareholder Newsletter
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials
SpectraScience Awarded Japanese Patent 4361683 for Its Optical Biopsy Forceps System
News
Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
Apr 30, 2009
San Diego, CA., April 30, 2009 -- SpectraScience, Inc. (OTC BulletinBoard: SCIE), a San Diego based medical device company, announced todaythat Iowa’s Des Moines Register published an article reporting that its LUMAcervical imaging system is improving the accuracy of cancer exams at theUniversity of Iowa.
Since Last July, researchersat the University of Iowa have used the LUMA Cervical Imaging System in more than80 women – in conjunction with standard methods of detecting cervical cancer –to enhance their ability to find cancer and precancerous disease.
Dr. Colleen Kennedy, primaryinvestigator for the LUMA study at the university, said in the article that,“The hope is that LUMA will aid in the detection of pre-cancer so that itdoesn’t develop into “full-blown” cancer and also to help in the early detectionof existing cancer so that it’s identified early when treatment is better.”
The trial at the University ofIowa is expected to be complete in 2010, with analysis from the first year ofthe study being available in September 2009, according to Kennedy.
Jim Hitchin, CEO ofSpectraScience, said that, “We arepleased with the progress of the University’s study and look forward to thepreliminary results this September. We are encouraged to see an increasinglevel of attention in the healthcare community related to the LUMA cervicalimaging system. Each year precancerous cervical tissue goes undiagnosed in200,000 American women. The LUMA system, which provides an objective method of screening cervical tissue, can help todramatically reduce this number. Webelieve this will result in improving the quality of healthcare to the patientand reducing overall costs to the system by avoiding the expense of treatinglater stage cancers.”
In the article, Kennedy addedthat “It really doesn’t add any discomfort or significant time to the patients.It literally adds maybe two minutes.” For the complete article, go to http://www.desmoinesregister.com/apps/pbcs.dll/article?AID=2009904290333.
This news release contains forward-looking statementswithin the meaning of Section 27A of the Securities Act of 1933, as amended,and Section 21E of the Securities Exchange Act of 1934, as amended. Theseforward-looking statements involve risks and uncertainties that may causeSpectraScience's actual results to differ materially from results discussed inforward-looking statements. Readers are urged to carefully review and considerthe various disclosures made by SpectraScience in this news release, its mostrecent Form 10-K and in SpectraScience's other reports filed with theSecurities and Exchange Commission ("SEC") that attempt to adviseinterested parties of the risks and factors that may affect SpectraScience'sbusiness. These forward-looking statements are qualified in their entirety bythe cautions and risk factors filed by SpectraScience in its annual report onForm 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diegobased medical device company that designs, develops, manufactures and marketsspectrophotometry systems capable of determining whether tissue is normal,pre-cancerous or cancerous without physically removing tissue from the body.The WavSTAT Optical Biopsy System uses light to optically scan tissue andprovide the physician with an immediate analysis. With FDA approval for sale inthe U.S. and the CE Mark for the European Union, the WavSTAT System is thefirst commercially available product that incorporates this innovativetechnology for clinical use. The Company's LUMA imaging technology has receivedFDA approval for an optical non-invasive system that is proven to moreeffectively detect cervical cancer precursors than conventional methodsavailable in the market today.
Contact:
SpectraScience, Inc.
Jim Hitchin, ChiefExecutive Officer
(858) 847-0200 x 201
Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387